Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity.
The kinetic parameters (Km and V) of human arylsulphatase B (4-sulpho-N-acetylgalactosamine sulphatase) activity in cultured skin fibroblasts were determined with a variety of substrates matching structural aspects of the physiological substrates in vivo chondroitin 4-sulphate and dermatan sulphate. More structurally complex substrates, in which several aspects of the aglycone structure of the natural substrate were maintained, were desulphated up to 4400 times faster than the minimum arylsulphatase-B-specific substrate, namely the monosaccharide N-acetylgalactosamine 4-sulphate. Aglycone structures that influence substrate binding and/or enzyme activity were an adjacent-residue C-6 carboxy group and a second but internal N-acetylgalactosamine 4-sulphate residue. Arylsulphatase B activity in fibroblast homogenates assayed with O-(beta-N-acetylgalactosamine 4-sulphate)-(1----4)-O-D-(beta-glucuronic acid)-(1----3)-O-D-N-acetyl[1-3H] galactosaminitol 4-sulphate derived from chondroitin 4-sulphate as substrate clearly distinguished Maroteaux-Lamy-syndrome patients from normal controls and other mucopolysaccharidosis patients. We recommend the use of the above trisaccharide substrate for both postnatal and prenatal diagnosis of Maroteaux-Lamy syndrome.
D002478:Cells, Cultured; D002803:Chondro-4-Sulfatase / Q000378:metabolism*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D007231:Infant, Newborn; D007700:Kinetics; D009083:Mucopolysaccharidoses / Q000175:diagnosis*; D009087:Mucopolysaccharidosis VI / Q000175:diagnosis* / Q000201:enzymology; D009844:Oligosaccharides / Q000378:metabolism; D011247:Pregnancy; D011296:Prenatal Diagnosis; D013429:Sulfatases / Q000378:metabolism*; D013462:Sulfur Radioisotopes
D009844:Oligosaccharides; D013462:Sulfur Radioisotopes; D013429:Sulfatases; D002803:Chondro-4-Sulfatase